LEVEMIR FLEXPEN (insulin detemir) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2005.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
Levemir FlexPen is a long-acting basal insulin analog (insulin detemir) administered via subcutaneous injection for the treatment of diabetes mellitus. It works by mimicking the body's natural basal insulin secretion, providing steady glucose control over approximately 24 hours. Levemir is positioned as a basal insulin therapy suitable for both type 1 and type 2 diabetes patients requiring insulin management. The FlexPen device offers patient convenience with a prefilled, reusable pen delivery system.
Insulin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine
Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes
A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Worked on LEVEMIR FLEXPEN at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo$1.0B Medicare spend — this is a commercially significant brand
Employment opportunities for Levemir FlexPen are concentrated in brand management, market access, managed care, and field-based roles (territory managers, specialty sales). MSL positions are important for diabetes education and provider engagement in the competitive basal insulin space. Currently, 0 positions are linked to this product in available job tracking data, reflecting the mature, commoditized nature of the insulin market where hiring often shifts to biosimilar and next-generation products as LOE approaches.